Is Protalix Biotherapeutics Stock a Good Investment?
Protalix Biotherapeutics Investment Advice | PLX |
- Examine Protalix Biotherapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Protalix Biotherapeutics' leadership team and their track record. Good management can help Protalix Biotherapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Protalix Biotherapeutics' business and its evolving consumer preferences.
- Compare Protalix Biotherapeutics' performance and market position to its competitors. Analyze how Protalix Biotherapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Protalix Biotherapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Protalix Biotherapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Protalix Biotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Protalix Biotherapeutics is a good investment.
Sell | Buy |
Strong Buy
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Protalix Biotherapeutics Stock
Researching Protalix Biotherapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company outstanding shares are owned by corporate insiders. The book value of Protalix Biotherapeutics was at this time reported as 0.57. The company last dividend was issued on the 20th of December 2019. Protalix Biotherapeutics had 1:10 split on the 20th of December 2019.
To determine if Protalix Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Protalix Biotherapeutics' research are outlined below:
| Protalix Biotherapeutics appears to be risky and price may revert if volatility continues | |
| About 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 |
Protalix Biotherapeutics Quarterly Accounts Payable |
|
Protalix Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Protalix Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Protalix Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Protalix Biotherapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Protalix Biotherapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-16 | 2022-03-31 | -0.04 | -0.05 | -0.01 | 25 | ||
2025-03-12 | 2024-12-31 | 0.07 | 0.09 | 0.02 | 28 | ||
2024-11-04 | 2024-09-30 | 0.06 | 0.03 | -0.03 | 50 | ||
2023-11-06 | 2023-09-30 | -0.07 | -0.04 | 0.03 | 42 | ||
2021-11-15 | 2021-09-30 | -0.12 | -0.09 | 0.03 | 25 | ||
2021-05-14 | 2021-03-31 | -0.17 | -0.14 | 0.03 | 17 | ||
2024-05-10 | 2024-03-31 | -0.02 | -0.06 | -0.04 | 200 | ||
2024-03-14 | 2023-12-31 | -0.03 | -0.07 | -0.04 | 133 |
Protalix Biotherapeutics Analyst Ratings
Protalix Biotherapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Protalix Biotherapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Protalix Biotherapeutics' financials, market performance, and future outlook by experienced professionals. Protalix Biotherapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Protalix Biotherapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a total capitalization of 197.42 M.Market Cap |
|
Protalix Biotherapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.08 | 0.09 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.07 | 0.06 |
Determining Protalix Biotherapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Protalix Biotherapeutics is a good buy. For example, gross profit margin measures Protalix Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Protalix Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Protalix Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Protalix Biotherapeutics. Check Protalix Biotherapeutics' Beneish M Score to see the likelihood of Protalix Biotherapeutics' management manipulating its earnings.
Evaluate Protalix Biotherapeutics' management efficiency
Protalix Biotherapeutics has Return on Asset of 0.031 % which means that on every $100 spent on assets, it made $0.031 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0764 %, implying that it generated $0.0764 on every 100 dollars invested. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.09 in 2025, whereas Return On Equity is likely to drop 0.06 in 2025. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.04 in 2025, whereas Total Assets are likely to drop slightly above 52.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.60 | 0.84 | |
| Tangible Book Value Per Share | 0.60 | 0.84 | |
| Enterprise Value Over EBITDA | 18.73 | 19.67 | |
| Price Book Value Ratio | 3.16 | 3.00 | |
| Enterprise Value Multiple | 18.73 | 19.67 | |
| Price Fair Value | 3.16 | 3.00 | |
| Enterprise Value | 122.1 M | 116 M |
The decision-making processes within Protalix Biotherapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Beta 0.725 |
Basic technical analysis of Protalix Stock
As of the 26th of March, Protalix Biotherapeutics holds the Semi Deviation of 2.5, risk adjusted performance of 0.1631, and Coefficient Of Variation of 542.34. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protalix Biotherapeutics, as well as the relationship between them.Protalix Biotherapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Protalix Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Protalix Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Protalix Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Protalix Biotherapeutics' Outstanding Corporate Bonds
Protalix Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Protalix Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Protalix bonds can be classified according to their maturity, which is the date when Protalix Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PL 1618 15 APR 26 Corp BondUS74368CBC73 | View | |
| US74368CAX20 Corp BondUS74368CAX20 | View | |
| US743674BE29 Corp BondUS743674BE29 | View | |
| US74368CAY03 Corp BondUS74368CAY03 | View | |
| PRXNA 3832 08 FEB 51 Corp BondUS74365PAE88 | View | |
| PL 5366 06 JAN 26 Corp BondUS74368CBQ69 | View | |
| PRXNA 4027 03 AUG 50 Corp BondUS74365PAD06 | View | |
| PRXNA 3257 19 JAN 27 Corp BondUS74365PAG37 | View |
Understand Protalix Biotherapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Protalix Biotherapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1631 | |||
| Market Risk Adjusted Performance | 0.7194 | |||
| Mean Deviation | 2.62 | |||
| Semi Deviation | 2.5 | |||
| Downside Deviation | 3.08 | |||
| Coefficient Of Variation | 542.34 | |||
| Standard Deviation | 3.39 | |||
| Variance | 11.49 | |||
| Information Ratio | 0.1806 | |||
| Jensen Alpha | 0.6126 | |||
| Total Risk Alpha | 0.6037 | |||
| Sortino Ratio | 0.1991 | |||
| Treynor Ratio | 0.7094 | |||
| Maximum Drawdown | 16.96 | |||
| Value At Risk | (4.14) | |||
| Potential Upside | 6.37 | |||
| Downside Variance | 9.46 | |||
| Semi Variance | 6.27 | |||
| Expected Short fall | (3.40) | |||
| Skewness | 0.0788 | |||
| Kurtosis | 0.5814 |
| Risk Adjusted Performance | 0.1631 | |||
| Market Risk Adjusted Performance | 0.7194 | |||
| Mean Deviation | 2.62 | |||
| Semi Deviation | 2.5 | |||
| Downside Deviation | 3.08 | |||
| Coefficient Of Variation | 542.34 | |||
| Standard Deviation | 3.39 | |||
| Variance | 11.49 | |||
| Information Ratio | 0.1806 | |||
| Jensen Alpha | 0.6126 | |||
| Total Risk Alpha | 0.6037 | |||
| Sortino Ratio | 0.1991 | |||
| Treynor Ratio | 0.7094 | |||
| Maximum Drawdown | 16.96 | |||
| Value At Risk | (4.14) | |||
| Potential Upside | 6.37 | |||
| Downside Variance | 9.46 | |||
| Semi Variance | 6.27 | |||
| Expected Short fall | (3.40) | |||
| Skewness | 0.0788 | |||
| Kurtosis | 0.5814 |
Consider Protalix Biotherapeutics' intraday indicators
Protalix Biotherapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Protalix Biotherapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Protalix Biotherapeutics Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 5th of November 2024 Other Reports | ViewVerify | |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 1st of July 2024 Other Reports | ViewVerify |
Protalix Stock media impact
Far too much social signal, news, headlines, and media speculation about Protalix Biotherapeutics that are available to investors today. That information is available publicly through Protalix media outlets and privately through word of mouth or via Protalix internal channels. However, regardless of the origin, that massive amount of Protalix data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protalix Biotherapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protalix Biotherapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protalix Biotherapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protalix Biotherapeutics alpha.
Protalix Biotherapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Protalix Biotherapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.